Gyger M, Baron C, Forest L, Lussier P, Lagacé F, Bissonnette I, Bélanger R, Bonny Y, Busque L, Roy D C, Perreault C
Department of Hematology and Research Center, Maisonneuve-Rosemont Hospital, University of Montreal, Quebec, Canada.
Exp Hematol. 1998 May;26(5):426-34.
Primary graft failure, secondary to either host-vs.-graft reaction or delayed engraftment, and graft-vs.-host disease (GVHD) are among the most difficult clinical problems to manage in the field of allogeneic bone marrow transplantation (BMT). Early diagnosis of both conditions would greatly improve their outcome. Using fluorescence in situ hybridization (FISH) with an X- and Y-probe mixture, we sequentially monitored chimerism of neutrophils and lymphoid cells from day 1 to 100 in 28 consecutive recipients of sex-mismatched unmanipulated bone marrow grafts. The objective was to quantitatively assess the evolution of chimerism during this crucial time interval and to determine whether chimerism patterns would be predictive of engraftment and GVHD. In recipients with primary graft failure (n=7), the presence of donor-type neutrophils and NK cells as well as the predominance of donor-type T cells distinguished patients who responded to G-CSF (n=5) from nonresponders (n=2). Furthermore, the clearance of host CD3+CD56- cells during days 5-10 posttransplantation was significantly hastened in patients who subsequently developed acute (delta=80%) or chronic (delta=81%) GVHD compared with patients without GVHD (delta=17%). Thus, our data suggest that molecular monitoring of the fate of host/donor hematopoietic cells in the early posttransplantation period could be useful in differentiating patients with delayed engraftment from those with irreversible rejection and in predicting the occurrence of GVHD as soon as day 10. This investigational approach may provide an appropriate basis on which to select adequate treatment for primary graft failure and high-risk candidates that could benefit from novel preemptive therapies for GVHD.
原发性移植物功能衰竭继发于宿主抗移植物反应或植入延迟,以及移植物抗宿主病(GVHD)是异基因骨髓移植(BMT)领域中最难处理的临床问题。对这两种情况的早期诊断将大大改善其预后。我们使用X和Y探针混合物进行荧光原位杂交(FISH),对28例连续接受性别不匹配的未处理骨髓移植受者从第1天到第100天的中性粒细胞和淋巴细胞嵌合体进行了连续监测。目的是定量评估这一关键时间间隔内嵌合体的演变,并确定嵌合体模式是否可预测植入和GVHD。在原发性移植物功能衰竭的受者(n = 7)中,供体型中性粒细胞和NK细胞的存在以及供体型T细胞的优势区分了对粒细胞集落刺激因子(G-CSF)有反应的患者(n = 5)和无反应者(n = 2)。此外,与无GVHD的患者(δ = 17%)相比,随后发生急性(δ = 80%)或慢性(δ = 81%)GVHD的患者在移植后第5 - 10天宿主CD3 + CD56 - 细胞的清除明显加快。因此,我们的数据表明,移植后早期对宿主/供体造血细胞命运进行分子监测可能有助于区分植入延迟的患者和不可逆排斥的患者,并在第10天就预测GVHD的发生。这种研究方法可能为选择针对原发性移植物功能衰竭的适当治疗以及可能从新型GVHD抢先治疗中获益的高危患者提供合适的依据。